Please tell us what you thought about today’s presentation by taking the survey below:
Join us for a PsychU webinar with Drs. Vladimir Maletic, Craig Chepke, and Jason Carter as they discuss the potential role of norepinephrine in Major Depressive Disorder, as part of the monoaminergic theory of depression.
Despite the efficacy of first-line anti-depressant treatments in MDD, many individuals continue to experience unresolved symptoms that may impair their daily functioning and increase the healthcare burden. In fact, the STAR*D study demonstrated approximately one third of patients with MDD achieved remission following treatment with first-line antidepressants, highlighting the need to address unresolved and persistent symptoms of depression.1 Recent studies have shown that norepinephrine, a neurotransmitter which regulates concentration, energy levels, and arousal, may play a crucial role in the persistence of depression symptoms.2
Our webinar aims to provide valuable insights into the complex nature of depression and the potential role of norepinephrine in the pathophysiology of depression.
References:
Serves as Clinical Professor, Psychiatry/Behavioral Science, University of South Carolina School of Medicine Greenville, SC
Board-Certified Psychiatrist, Fellow of the American Psychiatric Association, Private practice at Excel Psychiatric Associates in Huntersville, NC, Adjunct Associate Professor of Psychiatry for Atrium Health and University of North Carolina School of Medicine
Senior Medical Science Liaison, Neuroscience Field Medical Affairs
Vladimir Maletic and Craig Chepke are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Jason Carter is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Notifications
